HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Oragenics, Inc. (OGEN)
0.97  0.18  (22.78%) 07-09 17:44
Open: 0.79 High: 1.12
Pre.close: 0.79 Low: 0.795
Volume: 36,625,736 Ave vol: 3,757,411
52w High: 1.12 52w Low: 0.35
MA(50): 0.606 MA(200): 0.549
EPS: -0.377 P/E Ratio: 0
Company profile
Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Website: http://www.oragenics.com
Market Cap (M): 54
Shares Out (M): 55
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring compound for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against dental caries, or tooth decay. Oragenics, Inc. has collaboration agreements with Precigen, Inc. and its subsidiary, Intrexon Actobiotics NV to develop AG013; and a license agreement with LPThera LLC to develop LPT3-04. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Technical analysis
Overall: Outperform
MA: Bullish MACD: Bullish
KDJ: Bullish RSI: Bullish
Target 1: 1.31 Target 2: 1.53
Resist 1: 1.12 Resist 2: 1.31
Support 1: 0.74 Support 2: 0.50
Company key metrics
Revenue per Share: 0
Net Income per Share: -0.3681
Cash per Share: 0.432
Book Value per Share: 0.4075
Price to Sales: 0
Price to Book Value: 1.0797
Earnings Yield: -0.8367
Dividend Yield: -22.2099
Debt to Equity: 0.1463
Debt to Assets: 0.1276
Financial analysis
Price to Book Value: Outperform
Return on Assets: Underperform
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Neutral
Debt to Equity: Neutral
Stock Charts
Headline news
Wed, 08 Jul 2020
Why Oragenics, Inc. (OGEN) Is in Such Horrid Condition: Rise 2.65% - The News Heater

Thu, 09 Jul 2020
Is Oragenics Inc (OGEN) Stock a Good Buy? - InvestorsObserver

Tue, 07 Jul 2020
Do Oragenics Inc. (OGEN) beta value of 0.51 signposts another twist? - The InvestChronicle

Wed, 01 Jul 2020
Buy or Sell Oragenics, Inc. (OGEN) Stock Now? Don't Try to Be a Top Gun - The News Heater

Wed, 10 Jun 2020
Price Trends About Oragenics, Inc. (OGEN) You Should Know - The News Heater

Mon, 29 Jun 2020
Market Reactions to Oragenics Inc (OGEN) Stock Getting a Bullish Rating - InvestorsObserver

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.